Skip to main content

8 Result(s)

within Hiroki Nagai Remove this filter Cancer Research Remove this filter

and

  1. No Access

    Article

    Inflammatory prognostic factors in advanced or recurrent esophageal squamous cell carcinoma treated with nivolumab

    In Japan, nivolumab administration is the standard treatment for patients with unresectable advanced or recurrent esophageal squamous cell carcinoma (ESCC) who are refractory or intolerant to fluoropyrimidines...

    Tatsuki Ikoma, Mototsugu Shimokawa, Toshihiko Matsumoto… in Cancer Immunology, Immunotherapy (2023)

  2. Article

    Open Access

    Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan

    RAS/BRAFV600E mutations are the most remarkable oncogenic driver mutations in colorectal cancer (CRC) and play an important role in treatment selection. No data are available regarding the clinical and prognostic...

    Tatsuki Ikoma, Mototsugu Shimokawa, Masahito Kotaka, Toshihiko Matsumoto… in BMC Cancer (2021)

    Download PDF (1934 KB) View Article

  3. No Access

    Article

    Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update

    Over the last two decades, molecular-targeted agents have become mainstream treatment for many types of malignancies and have improved the overall survival of patients. However, most patients eventually develo...

    Hiroki Nagai, Manabu Muto in International Journal of Clinical Oncology (2018)

  4. No Access

    Article

    Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab

    Nivolumab is a monoclonal antibody directed against programmed death-1 that has been shown to improve survival in patients with metastatic melanoma. However, the efficacy of nivolumab and other agents in melan...

    Motoo Nomura, Atsushi Otsuka, Tomohiro Kondo… in Cancer Chemotherapy and Pharmacology (2017)

  5. No Access

    Article

    Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901

    Single-agent chemotherapy with third-generation non-platinum agents, such as docetaxel, vinorelbine, is a standard therapeutic option for elderly patients with non-small-cell lung cancer (NSCLC). Subset analys...

    Young Hak Kim, Masataka Hirabayashi, Shinji Kosaka… in Cancer Chemotherapy and Pharmacology (2013)

  6. No Access

    Article

    Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer

    Several cases have been reported in which central nervous system (CNS) metastases of non-small cell lung cancer (NSCLC) resistant to gefitinib were improved by erlotinib. However, there has been no study in wh...

    Yosuke Togashi, Katsuhiro Masago, Satohiro Masuda… in Cancer Chemotherapy and Pharmacology (2012)

  7. No Access

    Article

    Safety of erlotinib treatment in outpatients with previously treated non-small-cell lung cancer in Japan

    Erlotinib is the first epidermal growth factor receptor–tyrosine kinase inhibitor shown to provide a survival benefit for advanced non-small-cell lung cancer (NSCLC) patients. Adverse drug reactions of erlotin...

    Hiroki Nagai, Shiro Tanaka, Miyuki Niimi… in International Journal of Clinical Oncology (2011)

  8. No Access

    Article

    Phase I study of the combination of nedaplatin and gemcitabine in previously untreated advanced squamous cell lung cancer

    The objectives of this phase I trial were to evaluate the toxicity of the nedaplatin/gemcitabine regimen, determine the maximum tolerated doses (MTDs) of these agents, and observe the anti-tumor effects of thi...

    Katsuhiro Masago, Shiro Fujita, Young Hak Kim… in Cancer Chemotherapy and Pharmacology (2011)